DMD Trials

Select which type of trials you want to search for using the buttons below

Location Trial Status:

= Fully recruited

= Recruiting

= Not yet recruiting

= Enrolling by invitation

= Completed / Terminated


Showing all 5 trials

AUSNMD logo rosette

Pfizer - Fordadistrogene Movaparvovec (PF-06939926)

A Phase 2, multicenter, single-arm study to evaluate the safety and dystrophin expression after Fordadistrogene Movaparvovec (PF-06939926) administration in male participants with early stage Duchenne Muscular Dystrophy

Summary

This is a gene therapy study that studies the safety and effectiveness of Fordadistrogene Movaparvovec (PF-06939926) in boys with DMD. It is a single-arm, non-randomized, open-label study, meaning that all participants will be receiving the gene therapy drug.

Study Number: NCT05429372

Learn More
Overall Trial Status
Recruiting
Trial Sponsor
Pfizer
Age
2 to under 4 years
Mutation Specific
All treatment types, Exclusions apply for some mutations in exons 9-13 and 29-30; please see exclusion criteria for more details.
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant
AUSNMD logo rosette

Sarepta - ESSENCE

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy

Summary

The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053 compared to placebo in Duchenne muscular dystrophy (DMD) patients with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively. Part 1 is double-blind and randomised; Part 2 is open-label.

Study Number: NCT02500381

Learn More
Overall Trial Status
Recruiting
Trial Sponsor
Sarepta Therapeutics
Age
7-13
Mutation Specific
Mutation specific therapies, Must be amenable to exon 45 or exon 53 skipping
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant
AUSNMD logo rosette

NS Pharma - RACER53

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)

Summary

This is a Phase 3 study that investigates the safety and efficacy of Viltolarsen in participants aged 4 to less than (<) 8 years old. The study has two groups: one group will take Viltolarsen, which skips Exon 53 out-of-frame mutations, and the other group will take a placebo. All participants will have weekly intravenous (IV) infusions of 80mg/kg Viltolarsen or placebo for 48 weeks. At the end of the study, participants may be asked to enrol in an open-label extension study, in which all participants will be taking Viltolarsen.

Study Number: NCT04060199

Learn More
Overall Trial Status
Recruiting
Trial Sponsor
NS Pharma, Inc.
Age
4 to 7 years
Mutation Specific
Mutation specific therapies, Must be amenable to exon 53 skipping
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
AUSNMD logo rosette

ReveraGen - Vamorolone (VBP15-004)

A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)

Summary

This Phase 2b study is designed to evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of vamorolone in comparison to corticosteroids and placebo treatments over a 24 week period. The study will also evaluate the persistence of the effect of vamorolone over a period of 48 weeks. 

The study is designed to compare 2 different doses of Vamorolone to a standard dose of corticosteroids (prednisone at 0.75 mg/kg/day) and to a placebo. Across all sites, this trial aimed to recruit a total of 120 ambulant DMD patients ages 4 to <7 years.

Study Number: NCT03439670

Learn More
Overall Trial Status
Trial complete
Trial Sponsor
ReveraGen BioPharma, Inc.
Age
4 to under 7 years
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
AUSNMD logo rosette

PTC - Ataluren (PTC124-041)

A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension

Summary

This study is a randomized, double-blind, placebo-controlled, 72-week study, followed by a 72-week open-label period. The purpose is to characterize the long-term effects of ataluren-mediated dystrophin restoration on disease progression.

Study Number: NCT03179631

Learn More
Overall Trial Status
Trial complete
Trial Sponsor
PTC Therapeutics, Inc.
Age
5 and above
Mutation Specific
Mutation specific therapies, Nonsense mutations only
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant

We have placed cookies on your computer to help make this website better. For more information please click here

By continuing to use this site or closing this panel, we'll assume you're OK to continue. You can view our full privacy policy here